Was wird aus den JIA-Patienten im erwachsenen Alter?

Zusammenfassung

Die juvenile idiopathische Arthritis (JIA) gilt mittlerweile als gut zu behandelnde Erkrankung. Allerdings hat ein doch beträchtlicher Anteil der JIA-Patienten als Erwachsene residuale Schäden, teils weiterbestehende Krankheitsaktivität, teils vielfältige Einschränkungen in ganz unterschiedlichen Bereichen des täglichen Lebens. In diesem Artikel zeigen wir einen kurzen Überblick zum Thema Langzeit-Outcome und Prognose der JIA.

Summary

Juvenile idiopathic arthritis is said to be a good treatable disease. However, a good part of JIA patients suffer from residual damage, ongoing disease activity and further problems in different parts of life, during adulthood. In this article, we show an overview of the knowledge concerning longtime outcome and prognosis of JIA.

Schlüsselwörter

JIA - Outcome - Prognose

Keywords

Juvenile idiopathic arthritis (JIA) - outcome - prognosis

• Literatur

• 1 Consolaro A, Bracciolini G, Ruperto N. et al. Paediatric Rheumatology International Trials Organization. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012; 64: 2366-2374.
• 2 Consolaro A, Ruperto N, Bracciolini G. et al. For the Paediatric Rheumatology International Trials Organization (PRINTO). Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis 2014; 73: 1380-1383.
• 3 Consolaro A, Negro G, Chiara Gallo M. et al. Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score. Arthritis Care Res (Hoboken) 2014; 66: 1703-1709.
• 4 Wallace CA, Giannini EH, Huang B. et al. Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organization. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 929-936.
• 5 Mina R, Klein-Gitelman MS, Ravelli A. et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 683-693.
• 6 Lazarevic D, Pistorio A, Palmisani E. et al. Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013; 72: 686-693.
• 7 Viola S, Felici E, Magni-Manzoni S. et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 2092-2102.
• 8 Gutiérrez-Suárez R, Ruperto N, Gastaldi R. et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2989-2996.
• 9 Rider LG, Lachenbruch PA, Monroe JB. et al. IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009; 60: 3425-3435.
• 10 Hashkes PJ, Wright BM, Lauer MS. et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010; 62: 599-608.
• 11 Thomas E, Symmons DP, Brewster DH. et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow-up study. J Rheumatol 2003; 30: 958-965.
• 12 Lomater C, Gerloni V, Gattinara M. et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000; 27: 491-496.
• 13 Minden K, Niewerth M, Listing J. et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46: 2392-2401.
• 14 Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41: 1428-1435.
• 15 Lurati A, Salmaso A, Gerloni V. et al. Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009; 36: 1532-1535.
• 16 Arkela-Kautiainen M, Haapasaari J, Kautiainen H. et al. Favourable social functioning and health related quality of life of patients with JIA in early adulthood. Ann Rheum Dis 2005; 64: 875-880.
• 17 Flatø B, Lien G, Smerdel-Ramoya A. et al. Juvenile psoriatic arthritis: long-term outcome and differentiation from other subtypes of juvenile idiopathic arthritis. J Rheumatol 2009; 36: 642-650.
• 18 Selvaag AM, Aulie HA, Lilleby V, Flatø B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 2014 Oct 31.
• 19 Foster HE, Marshall N, Myers A. et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003; 48: 767-775.
• 20 Flatø B, Hoffmann-Vold AM, Reiff A. et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 2006; 54: 3573-3582.
• 21 Bertilsson L, Andersson-Gäre B, Fasth A. et al. Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years. J Rheumatol 2013; 40: 715-724.
• 22 Simon D, Fernando C, Czernichow P. et al. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with long-term glucocorticoids. J Rheumatol 2002; 29: 1296-1300.
• 23 Zak M, Müller J, Karup Pedersen F. et al. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm Res 1999; 52: 80-85.
• 24 Sanner H, Gran JT, Sjaastad I. et al. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009; 48: 1541-1547.
• 25 Mathiesen P, Hegaard H, Herlin T. et al. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 2012; 41: 50-58.
• 26 Kotaniemi K, Sihto-Kauppi K, Salomaa P. et al. The frequency and outcome of uveitis in patients with newly diagnosed juvenile idiopathic arthritis in two 4-year cohorts from 1990-1993 and 2000-2003. Clin Exp Rheumatol 2014; 32: 143-147.
• 27 Vitale AT, Graham E, de Boer JH. et al. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm 2013; 21: 478-485.
• 28 Skarin A, Elborgh R, Edlund E. et al. Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm 2009; 17: 104-108.
• 29 Paroli MP, Abbouda A, Restivo L. et al. Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications. Ocul Immunol Inflamm 2015; 23: 74-81.
• 30 Barsalou J, Bradley TJ, Silverman ED. Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Res Ther 2013; 15: 212
• 31 Candell Chalom E, Periera B, Rettig P. et al. Educational, vocational and socioeconomic status and quality of life in adults with childhood-onset systemic lupus erythematosus. Pediatr Rheumatol Online J 2004; 2: 207-226.
• 32 van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis 2014 Jun 24.
• 33 Russo RA, Katsicas MM. Global damage in systemic juvenile idiopathic arthritis: preliminary early predictors. J Rheumatol 2008; 35: 1151-1156.